Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Oscar Health's bronze plan monthly churn rate remain below 2% through Q2 2026?
Current Prediction
Why This Question Matters
Bronze plans grew from 25% to 39% of Oscar's book — the largest mix shift. The Gravy Gauge flags higher deductible bronze plans as more churn-prone. If bronze monthly churn exceeds 2% (management's pre-ARPA benchmark), the revenue composition shift is destroying value. If churn stays below 2%, it validates that Oscar's product design and member experience can retain price-sensitive members even without enhanced subsidies.
Prediction Distribution
Individual Predictions(9 runs)
Management's pre-ARPA churn benchmark of 1-2% monthly is their stated expectation. The question is whether this benchmark holds for a population that has dramatically shifted toward bronze plans after the subsidy cliff. Bronze members are by definition more price-sensitive — they chose the lowest-cost option. When they start incurring healthcare costs (Q2, after deductibles start being met), they may exit. The 2% threshold is the upper end of the pre-ARPA range. Given the unprecedented subsidy cliff and bronze-heavy mix, I slightly lean toward churn exceeding 2%.
The 2% monthly threshold is the upper end of the pre-ARPA benchmark (1-2%). For bronze churn to stay below 2%, it needs to behave like pre-ARPA overall churn. But bronze members in a post-subsidy environment face a unique combination of higher premiums (no enhanced subsidies) and high deductibles. This is more stressful than pre-ARPA conditions. However, Oscar's innovative product design (lifestyle products, member experience) may create stickier relationships than traditional bronze plans. True coin-flip.
The key insight is that the 400K churn expected in Q1 removes the most price-sensitive members first — those who don't pay at all after the grace period. The members remaining in Q2 are those who actively chose to pay. This self-selection may mean the remaining bronze population is more committed than average. However, the CMS program integrity initiatives are reducing SEP re-enrollment, making churn one-directional. And Q2 is when healthcare utilization ramps, creating dissatisfaction with high-deductible plans. Slightly lean NO — churn may exceed 2%.
Bronze members in the post-subsidy environment face a double hit: higher premiums AND high deductibles. The grace period ending in Q1 will flush out non-payers, but the remaining members still face cost pressure throughout Q2. Monthly churn of 2% is the high end of the pre-ARPA benchmark — for an unprecedented subsidy cliff situation, exceeding this benchmark seems plausible. Slight lean NO.
Oscar's broker expansion (60%) and product innovation (lifestyle products) may create differentiation that reduces churn versus generic bronze plans. The company's AI-driven member experience (86% question completion, 67% response time reduction) could improve satisfaction and retention. Pre-ARPA churn was 1-2%, and the 2% threshold provides some buffer. However, this is genuinely uncertain. Slight lean YES given product differentiation.
The resolution criteria is somewhat ambiguous — Oscar may not explicitly disclose bronze-specific churn rates, in which case this market may be difficult to resolve. Setting that aside, the structural dynamics are negative for bronze retention: price-sensitive population, subsidy cliff, high deductibles, and Q2 utilization ramp. The analysis's concern about revenue quality from the bronze mix shift is well-founded. Lean NO.
Bronze members are price-sensitive. Post-subsidy conditions are tougher than pre-ARPA. But Oscar's products may help retention. Slight lean NO given structural headwinds.
Genuinely uncertain. The 2% threshold is at the upper end of pre-ARPA benchmarks. Post-subsidy conditions are worse but Oscar's products are better. True coin-flip with low confidence.
The combination of subsidy cliff impact, bronze price sensitivity, and Q2 utilization ramp creates headwinds for staying below 2% churn. The pre-ARPA benchmark may not apply in a more stressed environment. Lean NO.
Resolution Criteria
Resolves YES if Oscar Health discloses (in Q2 2026 earnings call, 10-Q, or investor presentation) that bronze plan monthly churn averaged below 2.0% for April-June 2026, or if total plan churn data implies bronze churn below this level. Resolves NO if bronze churn averaged 2.0% or above, or if management describes bronze churn as exceeding pre-ARPA benchmarks.
Resolution Source
Oscar Health Q2 2026 earnings release, 10-Q, or earnings call transcript
Source Trigger
Bronze plan churn rate — With bronze now 39% of the book (up from 25%), higher-than-expected bronze churn would signal adverse selection and revenue leakage
Full multi-lens equity analysis